Antares Pharma Receives Payment from Teva for Commercial Development of Vibex Auto-Injector Product

- Second in a Series of Products to Move Forward with Teva -
EWING, N.J.--(Business Wire)--
Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has received a
payment from Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), which will be
applied to the design and purchase of commercial tooling and assembly equipment
related to an undisclosed, fixed, single-dose, disposable injector product using
Antares` Vibex Autoinjector platform. The payment of approximately $4 million is
related to an amendment to the original License, Development and Supply
Agreement signed in July 2006 between the two companies. Pursuant to the
amendment, the payment mostly relates to reimbursement for commercial tooling
previously paid for by Antares and an advance for the purchase of new tooling
and automation equipment. The balance of the payment is an advance relating to
design and development work associated with the purchased equipment. Teva will
own the dedicated commercial tooling and assembly equipment, and Antares will
continue to receive potential future royalty payments on Teva`s net sales of the
undisclosed product as well as revenues for each device sold.

"Following the recent FDA approval of the Tev-Tropin Tjet Injector system
(needle-free hGH), we are pleased to have Teva`s financial and commercial
commitment for our second injector product, which uses our proprietary Vibex
platform. It is also a testimony to the focused and dedicated efforts of the
management team here at Antares," said Dr. Paul K. Wotton, Ph.D., President and
Chief Executive Officer. "We look forward to making continued progress as we
execute our strategic plan to build a stable, growing business while increasing
shareholder value," concluded Dr. Wotton.

About Antares Pharma

Antares Pharma is a product development company committed to improving
pharmaceuticals through its patented drug delivery systems. Antares has multiple
development partnerships with leading pharmaceutical companies. The Company`s
products are designed to improve safety and efficacy profiles by minimizing
dosing and reducing side effects while enabling improved patient compliance.
Antares has three validated drug delivery systems: the ATDTM Advanced
Transdermal Gel Delivery system; subcutaneous injection technology platforms,
including VibexTM disposable pressure-assisted auto injectors, ValeoTM/Vision
reusable needle-free injectors, and disposable multi-use pen injectors; and Easy
TecTM oral disintegrating tablets (ODT). Two of the systems have generated
FDA-approved products. Antares Pharma has corporate headquarters in Ewing, New
Jersey, with subsidiaries performing research, development, manufacturing and
product commercialization activities in Minneapolis, Minnesota and Basel,
Switzerland.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top
20 pharmaceutical companies in the world and is the world's leading generic
pharmaceutical company. The Company develops, manufactures and markets generic
and innovative human pharmaceuticals and active pharmaceutical ingredients, as
well as animal health pharmaceutical products. Over 80 percent of Teva's sales
are in North America and Europe.

Antares' Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995:

This press release contains forward-looking statements within the meaning of the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include statements related to the potential
device sales and royalties, the Company`s strategic plan of building a stable
growing business, and other statements which are other than statements of
historical facts. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends," "plans,"
anticipates," "believes," "estimates," "predicts," "projects," "potential,"
"continue," and other similar terminology or the negative of these terms, but
their absence does not mean that a particular statement is not forward-looking.
Such forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties that may cause actual results to differ
materially from those anticipated by the forward-looking statements. Additional
information concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2008, and in the Company's other periodic
reports and filings with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this press
release, except as required by law.

Antares Pharma
Robert F. Apple, +1 609-359-3020
or
In-Site Communications
Lisa Wilson, + 1 917-543-9932
lwilson@insitecony.com

Copyright Business Wire 2009